OS Therapies updates OST-HER2 metastatic osteosarcoma program
OS Therapies, Inc. said it provided an update on its OST-HER2 metastatic osteosarcoma program and announced upcoming conference attendance by its management team and business development advisors.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.